[X]
|
QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
[_]
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE
ACT
|
Delaware
|
98-0381367
|
(State
or other jurisdiction
|
(IRS
Employer
|
of
incorporation or organization)
|
Identification
No.)
|
Page
|
||
Number
|
||
PART
I.
|
FINANCIAL
INFORMATION
|
|
Item
1.
|
Financial
Statements
|
|
Consolidated
Balance Sheet as of March 31, 2006 (unaudited)
|
2
|
|
Consolidated
Statements of Income and Other Comprehensive Income
|
||
for
the three months ended March 31, 2006 and 2005 (unaudited)
|
3
|
|
Consolidated
Statements of Cash Flows for the
|
||
three
months ended March 31, 2006 and 2005 (unaudited)
|
4
|
|
Notes
to Consolidated Financial Statements (unaudited)
|
5
|
|
Item
2.
|
Management's
Discussion and Analysis or Plan of Operations
|
17
|
Item
3.
|
Controls
and Procedures
|
21
|
PART
II.
|
OTHER
INFORMATION
|
21
|
Item
1.
|
Legal
Proceedings
|
21
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
21
|
Item
3.
|
Defaults
Upon Senior Securities
|
22
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
22
|
Item
5.
|
Other
Information
|
22
|
Item
6.
|
Exhibits
|
22
|
SIGNATURES
|
|
23
|
March
31,
|
||||
2006
|
||||
ASSETS
|
||||
(unaudited)
|
||||
CURRENT
ASSETS:
|
||||
Cash
& cash equivalents
|
$
|
26,085,746
|
||
Accounts
receivable, net of allowance for doubtful accounts of $398,509
|
11,848,040
|
|||
Other
receivable
|
1,058,775
|
|||
Inventory
|
1,377,426
|
|||
Advances
to suppliers
|
3,021,216
|
|||
Prepaid
expense
|
60,961
|
|||
Other
current assets
|
2,770
|
|||
Total
current assets
|
43,454,934
|
|||
PROPERTY
AND EQUIPMENT, net
|
4,894,079
|
|||
CONSTRUCTION
IN PROGRESS
|
2,236,125
|
|||
MARKETABLE
SECURITY
|
9,101,217
|
|||
INTANGIBLE
ASSETS
|
2,100,175
|
|||
TOTAL
ASSETS
|
$
|
61,786,530
|
||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||
CURRENT
LIABILITIES:
|
||||
Accounts
payable
|
$
|
777,648
|
||
Other
payables
|
3,408,113
|
|||
Accrued
expenses
|
473,253
|
|||
Total
current liabilities
|
4,659,014
|
|||
STOCKHOLDERS'
EQUITY:
|
||||
Preferred
stock, $0.0001 per share; authorized 5,000,000 shares; none issued
|
||||
Common
stock, $0.0001 per share; authorized 30,000,000 shares;
|
||||
issued
and outstanding 18,176,917
|
1,818
|
|||
Additional
paid-in capital
|
32,860,075
|
|||
Other
comprehensive income
|
6,781,292
|
|||
Statutory
reserve
|
2,892,854
|
|||
Retained
earnings
|
14,591,477
|
|||
Total
stockholders' equity
|
57,127,516
|
|||
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
61,786,530
|
||
|
BODISEN
BIOTECH, INC. AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF INCOME AND OTHER COMPREHENSIVE
INCOME
|
FOR
THE THREE MONTHS ENDED MARCH 31, 2006 AND
2005
|
Three
Months Ended March 31,
|
|||||||
2006
|
2005
|
||||||
(Unaudited)
|
(Unaudited)
|
||||||
Net
Revenue
|
$
|
10,535,360
|
$
|
4,701,675
|
|||
Cost
of Revenue
|
6,299,121
|
3,047,498
|
|||||
Gross
profit
|
4,236,239
|
1,654,177
|
|||||
Operating
expenses
|
|||||||
Selling
expenses
|
474,174
|
148,140
|
|||||
General
and administrative expenses
|
304,224
|
278,470
|
|||||
Total
operating expenses
|
778,398
|
426,610
|
|||||
Income
from operations
|
3,457,841
|
1,227,567
|
|||||
Non-operating
income (expense):
|
|||||||
Other
income (expense)
|
(124,541
|
)
|
(416,703
|
)
|
|||
Interest
income
|
28,063
|
—
|
|||||
Interest
expense
|
(678,720
|
)
|
(14,131
|
)
|
|||
Total
non-operating income (expense)
|
(775,198
|
)
|
(430,834
|
)
|
|||
Net
income
|
$
|
2,682,643
|
$
|
796,733
|
|||
Other
comprehensive income
|
|||||||
Foreign
currency translation (loss)
|
(40,500
|
)
|
—
|
||||
Unrealized
gain on marketable equity security
|
2,290,783
|
—
|
|||||
Comprehensive
Income
|
$
|
4,932,926
|
$
|
796,733
|
|||
Weighted
average shares outstanding :
|
|||||||
Basic
|
17,215,232
|
15,268,000
|
|||||
Diluted
|
17,374,691
|
15,529,458
|
|||||
Earnings
per share:
|
|||||||
Basic
|
$
|
0.16
|
$
|
0.05
|
|||
Diluted
|
$
|
0.15
|
$
|
0.05
|
|||
Three
Months Ended March 31,
|
|||||||
2006
|
2005
|
||||||
(unaudited)
|
(unaudited)
|
||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
|||||||
Net
income
|
$
|
2,682,643
|
$
|
796,733
|
|||
Adjustments
to reconcile net income to net cash
|
|||||||
provided
in operating activities:
|
|||||||
Depreciation
and amortization
|
103,161
|
77,509
|
|||||
Amortization
of debt discounts
|
603,886
|
—
|
|||||
Exchange
loss
|
124,541
|
—
|
|||||
Value
of vested option issued to directors
|
7,523
|
—
|
|||||
(Increase)
/ decrease in assets:
|
|||||||
Accounts
receivable
|
(4,300,470
|
)
|
(2,892,853
|
)
|
|||
Other
receivable
|
(14,144
|
)
|
—
|
||||
Inventory
|
(188,722
|
)
|
(200,253
|
)
|
|||
Advances
to suppliers
|
1,565,316
|
155,137
|
|||||
Other
assets
|
765
|
(551,707
|
)
|
||||
Increase
/ (decrease) in current liabilities:
|
|||||||
Accounts
payable
|
724,157
|
174,614
|
|||||
Other
payables
|
1,792
|
—
|
|||||
Accrued
expenses
|
61,118
|
34,773
|
|||||
Net
cash provided by operating activities
|
1,371,566
|
(2,406,047
|
)
|
||||
|
|||||||
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|||||||
Acquisition
of property and equipment
|
(43,776
|
)
|
(890,633
|
)
|
|||
Additions
to construction in progress
|
(349,147
|
)
|
—
|
||||
Net
cash used in investing activities
|
(392,923
|
)
|
(890,633
|
)
|
|||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|||||||
Payments
on note payable
|
(5,000,000
|
)
|
—
|
||||
Repayments
of loans to officers
|
—
|
968,000
|
|||||
Proceeds
from issuance of convertible note
|
—
|
3,000,000
|
|||||
Proceeds
from issuance of common stock
|
26,682,511
|
—
|
|||||
Payment
of offering costs
|
(2,747,227
|
)
|
—
|
||||
Proceeds
from the exercise of warrants
|
220,160
|
—
|
|||||
Net
cash provided by financing activities
|
19,155,444
|
3,968,000
|
|||||
Effect
of exchange rate changes on cash and cash equivalents
|
(325,238
|
)
|
—
|
||||
NET
INCREASE IN CASH & CASH EQUIVALENTS
|
19,808,849
|
671,320
|
|||||
CASH
& CASH EQUIVALENTS, BEGINNING BALANCE
|
6,276,897
|
2,121,811
|
|||||
CASH
& CASH EQUIVALENTS, ENDING BALANCE
|
$
|
26,085,746
|
$
|
2,793,131
|
|||
SUPPLEMENTAL
DISCLOSURE OF CASH FLOW INFORMATION:
|
|||||||
Interest
paid
|
$
|
112,500
|
$
|
37,794
|
|||
Income
taxes paid
|
$
|
—
|
$
|
—
|
Operating
equipment
|
10
years
|
Vehicles
|
8
years
|
Office
equipment
|
5
years
|
Buildings
|
30
years
|
Operating
equipment
|
$
|
929,960
|
||
Vehicles
|
404,655
|
|||
Office
equipment
|
68,188
|
|||
Buildings
|
4,169,606
|
|||
5,572,409
|
||||
Less
accumulated depreciation
|
(678,330
|
)
|
||
$
|
4,894,079
|
1. |
Requires
an entity to recognize a servicing asset or servicing liability each
time
it undertakes an obligation to service a financial asset by entering
into
a servicing contract.
|
2. |
Requires
all separately recognized servicing assets and servicing liabilities
to be
initially measured at fair value, if practicable.
|
3. |
Permits
an entity to choose ‘Amortization method’ or Fair value measurement
method’ for each class of separately recognized servicing assets and
servicing liabilities:
|
4. |
At
its initial adoption, permits a one-time reclassification of
available-for-sale securities to trading securities by entities with
recognized servicing rights, without calling into question the treatment
of other available-for-sale securities under Statement 115, provided
that
the available-for-sale securities are identified in some manner as
offsetting the entity’s exposure to changes in fair value of servicing
assets or servicing liabilities that a servicer elects to subsequently
measure at fair value.
|
5. |
Requires
separate presentation of servicing assets and servicing liabilities
subsequently measured at fair value in the statement of financial
position
and additional disclosures for all separately recognized servicing
assets
and servicing liabilities.
|
Rights
to use land
|
$
|
1,705,069
|
||
Fertilizers
proprietary technology rights
|
997,880
|
|||
|
2,702,949
|
|||
Less
Accumulated amortization
|
(602,774
|
)
|
||
|
$
|
2,100,175
|
Outstanding,
December 31, 2005
|
136,000
|
|||
Granted
|
—
|
|||
Forfeited
|
—
|
|||
Exercised
|
—
|
|||
Outstanding,
March 31, 2006
|
136,000
|
Outstanding
Options
|
Exercisable
Options
|
|||||
|
|
|||||
Exercise
Price
|
Number
|
Average
Remaining Contractual Life
|
Average
Exercise
Price
|
Number
|
Average
Exercise
Price
|
|
|
|
|
|
|
|
|
$5.00
|
100,000
|
3.17
|
$5.00
|
100,000
|
$5.00
|
|
$5.80
|
10,000
|
3.74
|
$5.80
|
10,000
|
$5.80
|
|
$6.72
|
26,000
|
4.51
|
$6.72
|
26,000
|
$6.72
|
Outstanding,
December 31, 2005
|
165,333
|
|||
Granted
|
—
|
|||
Forfeited
|
—
|
|||
Exercised
|
32,000
|
|||
Outstanding,
March 31, 2006
|
133,333
|
Outstanding
Warrants
|
Exercisable
Warrants
|
|||||
|
|
|||||
Exercise
Price
|
Number
|
Average
Remaining Contractual Life
|
Average
Exercise
Price
|
Number
|
Average
Exercise
Price
|
|
|
|
|
|
|
|
|
$7.50
|
133,333
|
4.69
|
$7.50
|
133,333
|
$7.50
|
i. |
Making
up cumulative prior years’ losses, if any;
|
ii. |
Allocations
to the “Statutory surplus reserve” of at least 10% of income after tax, as
determined under PRC accounting rules and regulations, until the
fund
amounts to 50% of the Company’s registered capital;
|
iii. |
Allocations
of 5-10% of income after tax, as determined under PRC accounting
rules and
regulations, to the Company’s “Statutory common welfare fund”, which is
established for the purpose of providing employee facilities and
other
collective benefits to the Company’s employees; and
|
iv. |
Allocations
to the discretionary surplus reserve, if approved in the stockholders’
general meeting.
|
Three
month periods ended March 31,
|
|||||||||||||||||||
2006
|
2005
|
||||||||||||||||||
Per
|
Per
|
||||||||||||||||||
Income
|
Shares
|
Share
|
Income
|
Shares
|
Share
|
||||||||||||||
Basic
earnings per share
|
|||||||||||||||||||
Net
income
|
$
|
2,682,643
|
$
|
796,733
|
|||||||||||||||
Weighed
shares outstanding
|
17,215,232
|
15,268,000
|
|||||||||||||||||
$
|
0.16
|
$
|
0.05
|
||||||||||||||||
Diluted
earnings per share
|
|||||||||||||||||||
Net
income
|
$
|
2,682,643
|
$
|
796,733
|
|||||||||||||||
Weighed
shares outstanding
|
17,215,232
|
15,268,000
|
|||||||||||||||||
Effect
of dilutive securities
|
|||||||||||||||||||
Options
|
89,537
|
261,458
|
|||||||||||||||||
Warrants
|
69,922
|
—
|
|||||||||||||||||
17,374,691
|
15,529,458
|
||||||||||||||||||
$
|
0.15
|
$
|
0.05
|
1. |
Requires
an entity to recognize a servicing asset or servicing liability each
time
it undertakes an obligation to service a financial asset by entering
into
a servicing contract.
|
2. |
Requires
all separately recognized servicing assets and servicing liabilities
to be
initially measured at fair value, if practicable.
|
3. |
Permits
an entity to choose ‘Amortization method’ or ‘Fair value measurement
method’ for each class of separately recognized servicing assets and
servicing liabilities:
|
4. |
At
its initial adoption, permits a one-time reclassification of
available-for-sale securities to trading securities by entities with
recognized servicing rights, without calling into question the treatment
of other available-for-sale securities under Statement 115, provided
that
the available-for-sale securities are identified in some manner as
offsetting the entity’s exposure to changes in fair value of servicing
assets or servicing liabilities that a servicer elects to subsequently
measure at fair value.
|
5. |
Requires
separate presentation of servicing assets and servicing liabilities
subsequently measured at fair value in the statement of financial
position
and additional disclosures for all separately recognized servicing
assets
and servicing liabilities.
|
(a) |
Exhibits
|
Exhibit
Number
|
Description
of Exhibit
|
3.1
|
Certificate
of Incorporation (incorporated by reference to Company’s Form SB-2 filed
September 3, 2002).
|
3.2
|
Amendment
to Certificate of Incorporation (incorporated by reference to Company’s
Form 10-KSB filed March 30, 2004).
|
3.3
|
By-Laws
(incorporated by reference to Company’s Form SB-2 filed September 3,
2002).
|
10.1
|
Loan
Agreement, dated as of September 28, 2003, between the Company and
Xianyang City Commercial Bank. (incorporated by reference to Company’s
Form 10-KSB filed March 30, 2004).
|
10.2
|
Bodisen
Biotech, Inc. 2004 Stock Option Plan (incorporated by reference to
Company’s Form 10-KSB filed March 31, 2005).
|
10.3
|
Form
of Bodisen Biotech, Inc. Nonstatutory Stock Option Agreement (incorporated
by reference to Company’s Form 10-KSB filed March 31,
2005).
|
21.1
|
Schedule
of Subsidiaries (incorporated by reference to Company’s Form 10-KSB filed
March 31, 2005).
|
31.1
|
Certification
of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a),
promulgated under the Securities and Exchange Act of 1934, as
amended
|
31.2
|
Certification
of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d
14(a),
promulgated under the Securities and Exchange Act of 1934, as
amended
|
32.1
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002 (Chief Executive
Officer)
|
32.2
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002 (Chief Financial
Officer)
|
|
Bodisen
Biotech, Inc.
|
|||
|
|
|
||
May
9, 2006
|
By:
|
/s/ Wang
Qiong
|
||
|
Wang
Qiong
Chief
Executive Officer (Principal Executive Officer)
|
|||
|
|
|
||
|
|
|||
|
|
|
||
May
9, 2006
|
By:
|
/s/ Yiliang
Lai
|
||
|
Yiliang
Lai
Chief
Financial Officer
(Principal
Financial and Accounting Officer)
|